Roche’s Columvi combo gains EC approval for DLBCL
Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx) combo…
Roche to Present 46 Abstracts, 12 Orals at ASH Meeting
Roche (OTCQX: RHHBY) will present 46 abstracts, including 12 oral presentations, at ASH…
Roche’s Columvi combo doubles survival in three-year DLBCL study
Roche (RHHBY) reported three-year follow-up from the phase III STARGLO study in relapsed/refractory…